Crizotinib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Crizotinib: From ALK/ROS1-Positive NSCLC to Gingival Fibromatosis
One-Sentence Summary
Crizotinib is an ALK/ROS1/MET tyrosine kinase inhibitor, established in non-small cell lung cancer (NSCLC) harboring ALK or ROS1 gene rearrangements (per the literature evidence in this pack). The TxGNN model's top-ranked prediction is Fibromatosis, Gingival, but this candidate currently has zero clinical trials and zero publications supporting it — it is a pure model-generated hypothesis with no known mechanistic link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | ALK/ROS1-positive non-small cell lung cancer (NSCLC) — inferred from literature evidence in this pack; not separately confirmed by Finland (Fimea) licensing data, as the drug is not marketed there |
| Predicted New Indication | Fibromatosis, Gingival |
| TxGNN Prediction Score | 99.81% |
| Evidence Level | L5 |
| Finland Market Status | 未上市 (Not Marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (blocking data gap). Based on the literature captured elsewhere in this evidence pack, crizotinib is a small-molecule ATP-competitive inhibitor of the receptor tyrosine kinases ALK, ROS1, and c-MET, with proven efficacy in ALK/ROS1-rearranged NSCLC.
For the top-ranked predicted indication, gingival fibromatosis, no clinical trial or publication evidence was found in any of the three source databases (ClinicalTrials.gov, ICTRP, PubMed). Gingival fibromatosis is a benign fibrous overgrowth condition with no established relationship to ALK, ROS1, or MET signaling. The TxGNN score reflects the model's internal graph-based similarity metric only — it does not correspond to any documented pharmacological, clinical, or case-based rationale linking crizotinib's known targets to this disease.
Given the absence of both mechanistic plausibility and empirical evidence, this candidate should not be interpreted as a validated repurposing signal at this time.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Finland Market Information
Crizotinib currently holds no marketing authorization in Finland (0 licenses on record; market status: 未上市/Not Marketed). No product, dosage form, or approved-indication data is available from Fimea for this drug.
Cytotoxicity
Crizotinib is an antineoplastic agent (per its known ALK/ROS1/MET tyrosine kinase inhibitor class, evidenced throughout the literature entries in this pack, e.g. its established use in ALK/ROS1-positive NSCLC).
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (ALK/ROS1/MET tyrosine kinase inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | No structured toxicity dataset is available in this pack; literature elsewhere among the other candidates references hepatotoxicity, QT prolongation/cardiotoxicity, and interstitial lung disease as known crizotinib safety signals — liver function, ECG/QTc, and pulmonary status should be considered, pending confirmation from the official package insert |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (gingival fibromatosis) is supported only by a TxGNN model score, with no clinical trials, no literature, and no mechanistic hypothesis connecting ALK/ROS1/MET inhibition to this disease (Evidence Level L5). In addition, TFDA package insert data (warnings/contraindications) is a blocking data gap, so this candidate cannot even enter S1 safety screening.
To proceed, the following is needed:
- TFDA/Fimea package insert (warnings, contraindications) — currently blocking
- Confirmed DrugBank mechanism of action data
- A preclinical or mechanistic rationale linking crizotinib's ALK/ROS1/MET targets to gingival fibromatosis pathology
- At minimum, case-report or in vitro evidence to escalate this candidate beyond L5
Note: This evidence pack contains other predicted indications for crizotinib with substantially stronger support — e.g., lung hilum carcinoma (L3, Proceed with Guardrails) and lung benign neoplasm / lung germ cell tumor (L4, Research Question) — largely reflecting crizotinib's already-established ALK/ROS1/MET-driven NSCLC biology. Several of these appear to be disease-ontology mapping mismatches (e.g., "lung benign neoplasm" literature is almost entirely about malignant ALK/ROS1+ NSCLC) and would need manual disease-label verification before advancing. If a report on one of these higher-evidence candidates is desired instead of the top TxGNN-ranked (but evidence-free) prediction, let us know.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.